Pink Sheet is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Avastin Half Dose Demonstrates Similar Treatment Effect To Full Dose In NSCLC

This article was originally published in The Pink Sheet Daily

Executive Summary

Results of Genentech’s AVAiL trial could potentially have an impact on physician prescribing patterns for bevacizumab.
Advertisement

Related Content

Avastin Misses Overall-survival Endpoint In Lung Cancer
Avastin Misses Overall-survival Endpoint In Lung Cancer
Genentech Resubmits Avastin sBLA For Metastatic Breast Cancer
Genentech Resubmits Avastin sBLA For Metastatic Breast Cancer
Roche Considers Pricing Flexibility For Avastin In Europe
Roche Considers Pricing Flexibility For Avastin In Europe
Genentech Adds Patient Assistance Program Along With Avastin Lung Cancer Indication
Genentech Adds Patient Assistance Program Along With Avastin Lung Cancer Indication

Topics

Advertisement
UsernamePublicRestriction

Register

PS065666

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel